Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis

Summary

A Phase Ib/IIa to evaluate the safety and tolerability of oral treatment with OST-122 in patients with moderate to severe ulcerative colitis over 28 days. This trial will also explore pharmacokinetics (PK) profile and preliminary therapeutic efficacy associated with OST-122 through biomarker analysis and clinical, endoscopic and histologic assessments.

Timeline

Start

2020-09-16

Primary completion

2022-12-27

Completion

2022-12-27

Drugs

Indications